HC Wainwright Lowers Structure Therapeutics (NASDAQ:GPCR) Price Target to $75.00

Structure Therapeutics (NASDAQ:GPCR) had its price target decreased by HC Wainwright from $80.00 to $75.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 213.94% from the company’s previous close.

Other equities research analysts have also issued reports about the company. William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating on the stock. Citigroup initiated coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $78.00.

Structure Therapeutics Stock Down 3.0%

Shares of Structure Therapeutics stock opened at $23.89 on Monday. The stock’s fifty day moving average is $20.98 and its 200-day moving average is $26.75. The firm has a market capitalization of $1.37 billion, a PE ratio of -32.28 and a beta of -1.69. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Analysts expect that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Barclays PLC increased its position in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after purchasing an additional 31,815 shares during the last quarter. Principal Financial Group Inc. increased its position in Structure Therapeutics by 230.0% in the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock worth $23,936,000 after purchasing an additional 380,115 shares during the last quarter. JPMorgan Chase & Co. increased its position in Structure Therapeutics by 302.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after purchasing an additional 25,500 shares during the last quarter. GAMMA Investing LLC increased its position in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in Structure Therapeutics in the 4th quarter worth about $40,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.